| __timestamp | Alnylam Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 50829000 |
| Thursday, January 1, 2015 | 60610000 | 57305000 |
| Friday, January 1, 2016 | 89354000 | 116145000 |
| Sunday, January 1, 2017 | 199365000 | 159362000 |
| Monday, January 1, 2018 | 382359000 | 206366000 |
| Tuesday, January 1, 2019 | 479005000 | 228244000 |
| Wednesday, January 1, 2020 | 588420000 | 293355000 |
| Friday, January 1, 2021 | 620639000 | 401715000 |
| Saturday, January 1, 2022 | 770658000 | 459856000 |
| Sunday, January 1, 2023 | 795646000 | 542705000 |
| Monday, January 1, 2024 | 975526000 | 492128000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Alnylam Pharmaceuticals and Exelixis, Inc. have shown distinct trajectories in their SG&A spending from 2014 to 2023. Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Exelixis experienced a more moderate increase of approximately 970%, indicating a more conservative growth strategy. By 2023, Alnylam's SG&A expenses were about 47% higher than Exelixis, highlighting its larger scale of operations. This analysis provides a window into how these companies balance growth with operational efficiency, offering valuable insights for investors and industry analysts alike. Understanding these trends is essential for stakeholders aiming to gauge the financial strategies of leading biotech firms.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Exelixis, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Insmed Incorporated or Exelixis, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.